Advertisement
U.S. markets closed
S&P Futures
5,959.75 +1.50 (+0.03%) Dow Futures
43,949.00 +48.00 (+0.11%) Nasdaq Futures
20,909.75 +15.75 (+0.08%) Russell 2000 Futures
2,406.10 +0.30 (+0.01%) Crude Oil
72.09 +0.40 (+0.56%) Gold
2,662.70 -13.60 (-0.51%)
BerGenBio ASA (BGBIO.OL)
Oslo - Oslo Delayed Price. Currency in NOK
Follow
At close: 04:25PM CET
| Previous Close | 7.75 |
| Open | 7.75 |
| Bid | 7.28 x 0 |
| Ask | 7.19 x 0 |
| Day's Range | 7.20 - 7.93 |
| 52 Week Range | 7.20 - 35.80 |
| Volume | |
| Avg. Volume | 208,279 |
| Market Cap | 282.209M |
| Beta (5Y Monthly) | 1.61 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -15.16 |
| Earnings Date | Nov 13, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 20.00 |
PR NewswireBerGenBio Announces Safety Data from Dose Escalation Phase 1b in First Line NSCLC Patients
BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical needs, announced today preliminary safety data from the Phase 1b portion of the BGBC016 study in first-line (1L) Non-Small Cell Lung Cancer (NSCLC) patients.
PR NewswireBerGenBio Second Quarter Results 2024: Solid clinical and financial progress
BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical needs, today announced financial results for the quarter and half year ended June 30, 2024, and provided a business update.
Advertisement
Advertisement
Advertisement
© 2024 Yahoo. All rights reserved.